RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Total non-current liabilities

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$108.9B
P/E ratio
SummaryFinancials
Period EndTotal non-current liabilities (Million USD)YoY (%)
Dec 31, 20242,559+59.70%
Dec 31, 20231,602+7.11%
Dec 31, 20221,496+25.67%
Dec 31, 20211,191+0.26%
Dec 31, 20201,187+32.18%
Dec 31, 2019898+30.13%
Dec 31, 2018690-0.87%
Dec 31, 2017696-9.09%
Dec 31, 2016766-14.78%
Dec 31, 2015899+3.29%
Dec 31, 2014870+54.08%
Dec 31, 2013565-48.29%
Dec 31, 20121,092+29.05%
Dec 31, 2011846+13.36%
Dec 31, 2010747

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)